- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 231/18 - One oxygen or sulfur atom
Patent holdings for IPC class C07D 231/18
Total number of patents in this class: 311
10-year publication summary
22
|
27
|
18
|
44
|
31
|
23
|
12
|
12
|
13
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Inflazome Limited | 91 |
28 |
Theravance Biopharma R&D IP, LLC | 517 |
14 |
Bristol-myers Squibb Company | 4863 |
8 |
Novartis AG | 11254 |
7 |
Arena Pharmaceuticals, Inc. | 368 |
7 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 160 |
7 |
The University of Queensland | 657 |
7 |
Northwestern University | 3276 |
6 |
Cardioxyl Pharmaceuticals, Inc. | 49 |
6 |
VALO Health, Inc. | 168 |
6 |
Bayer Pharma AG | 1085 |
5 |
The Johns Hopkins University | 5533 |
5 |
Sumitomo Pharma Co., Ltd. | 633 |
5 |
Hoffmann-La Roche Inc. | 3267 |
4 |
BASF SE | 20432 |
4 |
Abbott Laboratories | 2464 |
4 |
Bayer AG | 3209 |
4 |
Takeda Pharmaceutical Company Limited | 2943 |
4 |
Merial, Inc. | 225 |
4 |
Nippon Soda Co., Ltd. | 883 |
4 |
Other owners | 172 |